Peptide News Digest

#State-Medical-Board

2 stories

Regulatory · View digest

Ohio State Board of Pharmacy February 2026 Update Sets State-Level Peptide Compounding Guardrails Alongside Federal 503A Rules

The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.

Regulatory · View digest

Alabama Board of Medical Examiners Official Notice (May 26): Physicians, PAs, CRNPs, and CNMs Prohibited From Prescribing Non-FDA-Approved Research-Grade Peptides

The Alabama Board of Medical Examiners and Medical Licensure Commission issued a formal notice on May 26, 2026 prohibiting physicians, physician assistants, certified registered nurse practitioners, and certified nurse midwives from prescribing, administering, dispensing, recommending, or supplying any non-FDA-approved research-grade peptide to a patient. The notice explicitly declares patient consent forms acknowledging research-grade status ineffective and unable to mitigate professional or legal liability. Chairman Rogers cited the lack of FDA review as the basis: substances that have not gone through FDA review cannot be reliably verified for identity, manufacturing process, or risk profile. The state-level prohibition arrived alongside the FDA's April 23 removal of 12 peptides from Category 2 ahead of the July 23-24 PCAC meeting, illustrating that state-board enforcement is now layering on top of federal regulatory action.